The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3-and caspase 9-interacting sites
- Author(s)
- Silke, J; Hawkins, CJ; Ekert, PG; Chew, J; Day, CL; Pakusch, M; Verhagen, AM; Vaux, DL;
- Details
- Publication Year 2002-04-01,Volume 157,Issue #1,Page 115-124
- Journal Title
- JOURNAL OF CELL BIOLOGY
- Publication Type
- Journal Article
- Abstract
- The X-linked mammalian inhibitor of apoptosis protein (XIAP) has been shown to bind several partners. These partners include caspase 3, caspase 9, DIABLO/Smac, HtrA2/Omi, TAB1, the bone morphogenetic protein receptor, and a presumptive E2 ubiquitin-conjugating enzyme. In addition, we show here that XIAP can bind to itself. To determine which of these interactions are required for it to inhibit apoptosis, we generated point mutant XIAP proteins and correlated their ability to bind other proteins with their ability to inhibit apoptosis. partial derivativeRING point mutants of XIAP were as competent as their full-length counterparts in inhibiting apoptosis, although impaired in their ability to oligomerize with full-length XIAP. Triple point mutants, unable to bind caspase 9, caspase 3, and DIABLO/HtrA2/Omi, were completely ineffectual in inhibiting apoptosis. However, point mutants that had lost the ability to inhibit caspase 9 and caspase 3 but retained the ability to inhibit DIABLO were still able to inhibit apoptosis, demonstrating that IAP antagonism is required for apoptosis to proceed following UV irradiation.
- Publisher
- ROCKEFELLER UNIV PRESS
- Keywords
- PROTEIN LIGASE ACTIVITY; STRUCTURAL BASIS; CELL-DEATH; NMR STRUCTURE; BIR DOMAIN; INHIBITOR; SMAC/DIABLO; IAP; MUTAGENESIS; DEGRADATION
- Publisher's Version
- https://doi.org/10.1083/jcb.200108085
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2002-04-01 12:00:00